Personalized Care Plans for Patients With Relapsed/Refractory Follicular Lymphoma: Dr. Loretta J. Nastoupil, MD

Follicular lymphoma is a disease that affects 2.7 per 100,000 individuals each year, with a five-year survival rate of 89.7%. It is the most common subtype of indolent non-Hodgkin's lymphoma; about 22% of newly diagnosed non-Hodgkin lymphoma cases are follicular lymphoma. The development of novel therapies offers new treatment options for patients living with follicular lymphoma. In this interview, Dr. Loretta J. Nastoupil, MD, Section Chief of New Drug Development in the Department of Lymphoma/...
Continue reading

Tafasitamab/Lenalidomide for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Gilles Salles, MD, PhD

Recently, the FDA granted accelerated approval to tafasitamab-cxix (Monjuvi®, MorphoSys US Inc.) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplantation. In this interview with i3 Health, Gilles Salles, MD, PhD, principal investigator of the phase 2 L-MIND trial, on which the approval was based, discusses the significance of the approval, adverse events of note with tafasitamab/lenal...
Continue reading

Transplant-Ineligible Diffuse Large B-Cell Lymphoma: Tafasitamab/Lenalidomide Approved

The FDA has granted accelerated approval to tafasitamab-cxix (Monjuvi®, MorphoSys US Inc.) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, who are ineligible for autologous stem cell transplantation. The approval of tafasitamab, a CD19-directed cytolytic antibody, is based on efficacy data from the single-arm, international phase 2 L-MIND trial (NCT02399085), wh...
Continue reading

Rituximab/Lenalidomide/Ibrutinib Effective in DLBCL

A phase 2 study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting revealed that a combination of rituximab (Rituxan®, Genentech USA, Inc), lenalidomide (Revlimid®, Celgene Corporation), and ibrutinib (Imbruvica®, Janssen Biotech, Inc) demonstrates overall response in adult patients with previously untreated non-germinal center B-cell (non-GCB)–like subtype diffuse large B-cell lymphoma (DLBCL). Rituximab, which targets abnormal B cells and reduces their lifespan, is al...
Continue reading

Lenalidomide/Rituximab for Follicular Lymphoma and Marginal Zone Lymphoma: John P. Leonard, MD

This week, the FDA approved lenalidomide (Revlimid®, Celgene Corporation) in combination with a rituximab product for relapsed/refractory follicular lymphoma (FL) and relapsed/refractory marginal zone lymphoma (MZL). In this interview with i3 Health, John P. Leonard, MD, lead author of the AUGMENT trial, on which the approval was based, discusses the approval's importance and shares his advice for physicians treating patients with relapsed/refractory FL or MZL. Can you comment on the significanc...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.